The IL-23/-17 Axis in PsA: What Have We Learned in the Last 20 Years? [PDF]
Mediterr J RheumatolTheodoridou F, Katsouli O, Fragoulis GE.
europepmc +1 more source
Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis. [PDF]
ACG Case Rep JSrivoleti P, Dhillon N, Boneschansker L.
europepmc +1 more source
Sequential Paradoxical Eczema Following Interleukin-23, Interleukin-17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient. [PDF]
J DermatolPark S, Jo SJ.
europepmc +1 more source
A shared immunological context underlying IgA nephropathy. [PDF]
CEN Case RepShimizu A, Tsuboi N.
europepmc +1 more source
Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review. [PDF]
Medicine (Baltimore)Afzal MW +5 more
europepmc +1 more source
New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review. [PDF]
Dermatol Ther (Heidelb)Wang G, Youn SW, Chang CL, Saeki H.
europepmc +1 more source
The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study. [PDF]
An Bras DermatolPehlivan Ulutaş G +2 more
europepmc +1 more source
Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study. [PDF]
Dermatol Ther (Heidelb)Hsu CC, Huang YH, Tsai TF.
europepmc +1 more source
Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab. [PDF]
Crohns Colitis 360Han J +5 more
europepmc +1 more source